We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to ...

Detailed price information for Pacific Biosciences (PACB-Q) from The Globe and Mail including charting and trades.

SAN DIEGO, March 11, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) will participate at the Stifel 2025 Virtual CNS Forum at 1:30 p.m. Eastern Time on Tuesday, March 18, 2025. Chief ...

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on March 10, 2025, the Compensation Committee of the ...

On Dec 12, 2024, the US Food and Drug Administration (FDA) approved crinecerfont for adults and paediatric patients with ...

Neurocrine Biosciences has commenced the Phase I clinical trial of its oral, small molecule vesicular monoamine transporter 2 ...

Boys and young adult male patients with congenital adrenal hyperplasia receiving glucocorticoid treatment have lower bone mineral density than healthy individuals, an Italian study shows.

HBM Alpha Therapeutics Inc. signed a potential $395 million licensing deal Feb. 26 with an unnamed “business partner” for its endocrine asset, HAT-001, adding another contender to the congenital ...

The therapy—called HAT001 at HBMAT and HBM9013 at Harbour—is an anti-CRH-neutralizing antibody that is being considered for a range of disorders including congenital adrenal hyperplasia (CAH).

Researchers at Mount Sinai have identified gene pairs that may contribute to congenital heart disease through digenic inheritance. Their findings improve diagnostic accuracy, expand genetic research, ...